Targeted protein degradation via CRBN-modulating molecular glues has revolutionized therapeutic strategies, yet challenges remain in expanding their substrate scope. Here, the authors identify novel CRBN substrates and develop ABS-752, a prodrug activated in cirrhotic liver, demonstrating potent anti-cancer activity against hepatocellular carcinoma.
- Przemysław Glaza
- Roman Pluta
- Michał J. Walczak
